News

Mitochondrial transfer approved in U.K.; debate begins in U.S.


 

References

Debating the ethics

Dr. Mitalipov acknowledged the ethical concerns, but said that unlike other types of gene therapy, mitochondrial replacement therapy aims to eliminate the cause of the condition, “before it is actually passed to the child.”

While there are concerns that the technology could eventually lead to nonmedical genetic enhancements, he said, “it is up to society to regulate those issues.”

One of the most vocal critics of mitochondrial replacement techniques is Marcy Darnovsky, Ph.D., executive director of the Center for Genetics and Society in Berkeley, Calif.

“All of us should be concerned about the safety risks to any resulting children,” as well as social policy and the availability of the technique “breaking a widespread global agreement that we shouldn’t make genetic changes that will enter the human germline,” she said in an interview.

Moreover, a woman at risk of transmitting a mitochondrial disease who wants to have a healthy child is both emotionally and physically vulnerable. “Physicians treating these women have an elevated responsibility to make sure they are giving them the full picture,” she said.

In a statement issued shortly after the U.K. House of Lords approved the use of the procedure, Dr. Darnovsky said that “unlike experimental gene therapies where risks are taken on by consenting individuals, these techniques turn children into our biological experiments and forever alter the human germline in unknowable ways.”

Josephine Johnston

Josephine Johnston

But Josephine Johnston, director of research at the Hastings Center, a bioethics research institute in Garrison, N.Y., who studies ethical considerations related to assisted reproductive technology, said the U.K. approach “seems like a very reasonable plan.”

And she predicts that because of the way ART is regulated in the U.K., mitochondrial donation would be tightly restricted and would likely result in about 10 of these procedures being performed over the next few years.

While germline modification – manipulating the genetics of an embryo to make a change that will be inherited to the next generation – has been considered by many to be an ethical line not to be crossed, Ms. Johnston said she hopes people can move past the slippery slope objections.

“I hope we as a human community are sophisticated enough to understand that just because we said yes to one thing, doesn’t necessarily mean we have to say yes to everything that might come after it,” she said.

emechcatie@frontlinemedcom.com

Pages

Recommended Reading

President unveils details of precision medicine initiative
MDedge Family Medicine
Sore throat and left ear pain
MDedge Family Medicine
News about Rare Diseases for Frontline Readers
MDedge Family Medicine
Rare Disease Day (Feb. 28, 2015)
MDedge Family Medicine
Seeking a Diagnosis for Children with Rare Neurodevelopmental Disorders
MDedge Family Medicine
HPV-16 E6 seropositivity common before anal cancer develops
MDedge Family Medicine
More cancer patients surviving longer, but age-based disparities remain
MDedge Family Medicine
Targeted treatments improving ovarian cancer outcomes
MDedge Family Medicine
Genetic variant predisposes to vincristine-related neuropathy
MDedge Family Medicine
VIDEO: Search for genetic risk factors may improve vincristine therapy
MDedge Family Medicine